GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dermapharm Holding SE (XTER:DMP) » Definitions » Scaled Net Operating Assets

Dermapharm Holding SE (XTER:DMP) Scaled Net Operating Assets : 0.21 (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Dermapharm Holding SE Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Dermapharm Holding SE's operating assets for the quarter that ended in Sep. 2024 was €1,999 Mil. Dermapharm Holding SE's operating liabilities for the quarter that ended in Sep. 2024 was €1,534 Mil. Dermapharm Holding SE's Total Assets for the quarter that ended in Jun. 2024 was €2,207 Mil. Therefore, Dermapharm Holding SE's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2024 was 0.21.


Dermapharm Holding SE Scaled Net Operating Assets Historical Data

The historical data trend for Dermapharm Holding SE's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermapharm Holding SE Scaled Net Operating Assets Chart

Dermapharm Holding SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.03 0.78 0.74 0.63 1.04

Dermapharm Holding SE Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.68 0.22 0.18 0.21

Competitive Comparison of Dermapharm Holding SE's Scaled Net Operating Assets

For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dermapharm Holding SE's Scaled Net Operating Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Dermapharm Holding SE's Scaled Net Operating Assets falls into.



Dermapharm Holding SE Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Dermapharm Holding SE's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(2001.096-535.237)/1412.836
=1.04

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=2160.673 - 159.577
=2001.096

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=1615.625 - 963.958 - 116.43
=535.237

Dermapharm Holding SE's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Sep. 2024 )
=(Operating Assets (Q: Sep. 2024 )-Operating Liabilities (Q: Sep. 2024 ))/Total Assets (Q: Jun. 2024 )
=(1998.691-1534.017)/2207.102
=0.21

where

Operating Assets(Q: Sep. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=2123.052 - 124.361
=1998.691

Operating Liabilities(Q: Sep. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=1534.017 - 0 - 0
=1534.017

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dermapharm Holding SE Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Dermapharm Holding SE's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Dermapharm Holding SE Business Description

Address
Lil-Dagover-Ring 7, Grunwald, BY, DEU, 82031
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals and other healthcare products which drive key revenue, Herbal extracts, and Parallel import business. Branded pharmaceuticals and other healthcare products focus on the development, manufacturing, and marketing of branded pharmaceuticals and other healthcare products. Herbal extracts include the manufacturing of phytopharmaceuticals, nutraceuticals, and cosmetics products. Parallel import brands business operates under the AxiCorp brand.
Executives
Wilhelm Beier Supervisory Board
Dr. Hans-georg Feldmeier Board of Directors
Christof Dreibholz Board of Directors
Lothar Lanz Supervisory Board
Anja Schorn Board Member Themis Beteiligungs-AG
Hilde Neumeyer Board of Directors

Dermapharm Holding SE Headlines

No Headlines